FDA Accepts Genentech sBLA for Gazyva in SLE

Regulatory filing and timeline

FDA accepted Genentech's supplemental BLA for Gazyva (obinutuzumab) for systemic lupus erythematosus (SLE) based on Phase III ALLEGORY; an FDA decision is expected by December 2026. Gazyva is already approved for lupus nephritis in the US and EU.

ALLEGORY design

ALLEGORY (NCT04963296) was a randomized, double-blind, placebo-controlled Phase III trial of ~300 adults with SLE, randomized 1:1 to Gazyva plus standard therapy or placebo plus standard therapy for 52 weeks, with an open-label extension to 104 weeks; primary endpoint was SRI‑4 at week 52.

Key efficacy results

SRI‑4 responder rates at 52 weeks were 76.7% (Gazyva) vs 53.5% (placebo), adjusted difference 23.1% (95% CI 12.5–33.6, p<0.001). Secondary outcomes included higher DORIS remission (33.8% vs 13.8%, adj diff 19.9%), greater LLDAS (57.6% vs 25.0%, adj diff 32.6%), sustained glucocorticoid reduction to ≤7.5 mg/day (weeks 40–52), and fewer flares by BILAG (HR 0.58, p=0.002); median time to first flare was not estimable.

Safety and development context

Safety was consistent with Gazyva's established profile with no new signals; ALLEGORY data have been used for an EMA filing and add to other positive Phase III programs for obinutuzumab in immune-mediated diseases including REGENCY, INShore and MAJESTY; Gazyva is an anti‑CD20 Type II glycoengineered monoclonal antibody that induces direct B‑cell death and increased ADCC.